L
Lenny Dang
Researcher at Agios Pharmaceuticals
Publications - 65
Citations - 12028
Lenny Dang is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: Isocitrate dehydrogenase & IDH1. The author has an hindex of 30, co-authored 61 publications receiving 10429 citations. Previous affiliations of Lenny Dang include California Institute of Technology & Millennium Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang,David W. White,Stefan Gross,Bryson D. Bennett,Mark A. Bittinger,Edward M. Driggers,Valeria Fantin,Hyun Gyung Jang,Shengfang Jin,Marie C. Keenan,Kevin Marks,Robert M. Prins,Patrick S. Ward,Katharine E. Yen,Linda M. Liau,Joshua D. Rabinowitz,Lewis C. Cantley,Craig B. Thompson,Matthew G. Vander Heiden,Matthew G. Vander Heiden,Shinsan M. Su +20 more
TL;DR: It is shown that cancer-associated IDH1 mutations result in a new ability of the enzyme to catalyse the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG), and that the excess 2HG which accumulates in vivo contributes to the formation and malignant progression of gliomas.
Journal ArticleDOI
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
Christina M. Annunziata,R. Eric Davis,Yulia N. Demchenko,William T. Bellamy,Ana Gabrea,Fenghuang Zhan,Georg Lenz,Ichiro Hanamura,George E. Wright,Wenming Xiao,Sandeep S. Dave,Elaine M. Hurt,Bruce K. Tan,Hong Zhao,Owen W. Stephens,Madhumita Santra,David R. Williams,Lenny Dang,Bart Barlogie,John D. Shaughnessy,W. Michael Kuehl,Louis M. Staudt +21 more
TL;DR: It is demonstrated that addiction to the NF-kappaB pathway is frequent in myeloma and suggest that IKKbeta inhibitors hold promise for the treatment of this disease.
Journal ArticleDOI
NF-κB as a Therapeutic Target in Multiple Myeloma *
Teru Hideshima,Dharminder Chauhan,Paul G. Richardson,Constantine S. Mitsiades,Nicholas Mitsiades,Toshiaki Hayashi,Nikhil C. Munshi,Lenny Dang,Alfredo C. Castro,Vito Palombella,Julian Adams,Kenneth C. Anderson +11 more
TL;DR: These studies demonstrate that specific targeting of NF-κB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu.
Journal ArticleDOI
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang,Jeremy Travins,Byron DeLaBarre,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Stefanie Schalm,Erica Hansen,Kimberly Straley,Andrew Kernytsky,Wei Liu,Camelia Gliser,Hua Yang,Stefan Gross,Erin Artin,Véronique Saada,Elena Mylonas,Elena Mylonas,Elena Mylonas,Cyril Quivoron,Cyril Quivoron,Cyril Quivoron,Janeta Popovici-Muller,Jeffrey O. Saunders,Francesco G. Salituro,Shunqi Yan,Stuart Murray,Wentao Wei,Yi Gao,Lenny Dang,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Stéphane de Botton,Stéphane de Botton,Stéphane de Botton,Katharine E. Yen +38 more
TL;DR: Evidence is provided that inhibitors targeting mutant IDH2/R140Q could have potential applications as a differentiation therapy for cancer, and a small molecule, AGI-6780, that potently and selectively inhibits the tumor-associated mutant IDh2/ R140Q is developed.
Journal ArticleDOI
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Stefan Gross,Rob A. Cairns,Mark D. Minden,Edward M. Driggers,Mark A. Bittinger,Hyun Gyung Jang,Masato Sasaki,Shengfang Jin,David P. Schenkein,Shinsan M. Su,Lenny Dang,Valeria Fantin,Tak Mak +12 more
TL;DR: IDH1/2 mutations confer an enzymatic gain of function that dramatically increases 2-HG in AML, providing an explanation for the heterozygous acquisition of these mutations during tumorigenesis.